Alexander Nolte - Feb 1, 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Accounting Officer
Signature
/s/ Michael A. Metzger, Attorney-in-fact
Stock symbol
SNDX
Transactions as of
Feb 1, 2022
Transactions value $
$469,576
Form type
4
Date filed
2/3/2022, 04:31 PM
Previous filing
Nov 4, 2021
Next filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Other $12K +968 $12.39 968 Jan 31, 2022 Direct F1
transaction SNDX Common Stock Sale -$16.1K -968 -100% $16.65 0 Feb 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Award $474K +30K $15.79 30K Feb 2, 2022 Common Stock 30K $15.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 968 shares by the Reporting Person on 01/31/2022 pursuant to the Issuer's Employee Stock Purchase Plan.
F2 1/48th of the shares subject to the option shall vest monthly over a four-year period.